Advocate

Country: European Union

Language: Italian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

imidacloprid, moxidectin

Available from:

Bayer Animal Health GmbH

ATC code:

QP54AB52

INN (International Name):

imidacloprid, moxidectin

Therapeutic group:

Dogs; Cats; Ferrets

Therapeutic area:

Prodotti antiparassitari, insetticidi e repellenti

Therapeutic indications:

DogsFor cani affetti da o a rischio, misto infezioni parassitarie:il trattamento e la prevenzione dell'infestazione da pulci (Ctenocephalides felis),il trattamento di mordere i pidocchi (Trichodectes canis),il trattamento di orecchio acaro infestazione (Otodectes cynotis), rogna sarcoptica (causata da Sarcoptes scabiei var. canis), la demodicosi (causato da Demodex canis),la prevenzione della filariosi cardiopolmonare (L3 e L4 larve di Dirofilaria immitis),il trattamento delle microfilarie circolanti (Dirofilaria immitis),il trattamento dei cutanea dirofilariosis (stadi adulti di Dirofilaria repens)la prevenzione dell'cutanea dirofilariosis (L3 larve di Dirofilaria repens),la riduzione delle microfilarie circolanti (Dirofilaria repens),la prevenzione delle angiostrongylosis (L4 larve e adulti immaturi di Angiostrongylus vasorum),il trattamento di Angiostrongylus vasorum e Crenosoma vulpis,la prevenzione di spirocercosis (Spirocerca lupi),il trattamento di Eucoleus (syn. Capillaria) boehmi (adulti),il trattamento dell'occhio worm Thelazia callipaeda (adulti),il trattamento delle infezioni da nematodi gastrointestinali (L4 larve, adulti immaturi e adulti di Toxocara canis, Ancylostoma caninum e Uncinaria stenocephala, adulti di Toxascaris leonina e Trichuris vulpis). Il prodotto può essere utilizzato come parte di una strategia di trattamento per la dermatite allergica da pulci (FAD). CatsFor gatti che soffrono, o a rischio, misto infezioni parassitarie:il trattamento e la prevenzione dell'infestazione da pulci (Ctenocephalides felis),il trattamento di orecchio acaro infestazione (Otodectes cynotis),il trattamento della rogna notoedric (Notoedres cati),il trattamento della polmonaria Eucoleus aerophilus (syn. Capillaria aerophila) (adulti),la prevenzione della polmonaria malattia (L3/L4 larve di Aelurostrongylus abstrusus),il trattamento della polmonaria Aelurostrongylus abstrusus (adulti),il trattamento dell'occhio worm Thelazia callipaeda (adulti),la prevenzione della filariosi cardiopolmonare (L3 e L4 larve di Dirofilaria immitis),il trattamento delle infezioni da nematodi gastrointestinali (L4 larve, adulti immaturi e adulti di Toxocara cati e Ancylostoma tubaeforme). Il prodotto può essere utilizzato come parte di una strategia di trattamento per la dermatite allergica da pulci (FAD). FerretsFor furetti che soffrono, o a rischio, misto infezioni parassitarie:il trattamento e la prevenzione dell'infestazione da pulci (Ctenocephalides felis),la prevenzione della filariosi cardiopolmonare (L3 e L4 larve di Dirofilaria immitis).

Product summary:

Revision: 23

Authorization status:

autorizzato

Authorization date:

2003-04-02

Patient Information leaflet

                                OFFICIAL ADDRESS
Domenico Scarlattilaan 6
●
1083 HS Amsterdam
●
The Netherlands
An agency of the European Union
ADDRESS FOR VISITS AND DELIVERIES
Refer to www.ema.europa.eu/how-to-find-us
SEND US A QUESTION
Go to
www.ema.europa.eu/contact
TELEPHONE
+31 (0)88 781
6000
© European Medicines Agency,
2023. Reproduction is authorised provided the source is acknowledged.
Informazioni aggiornate su questo medicinale veterinario sono
disponibili sul sito web Veterinary
Medicines.
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                OFFICIAL ADDRESS
Domenico Scarlattilaan 6
●
1083 HS Amsterdam
●
The Netherlands
An agency of the European Union
ADDRESS FOR VISITS AND DELIVERIES
Refer to www.ema.europa.eu/how-to-find-us
SEND US A QUESTION
Go to
www.ema.europa.eu/contact
TELEPHONE
+31 (0)88 781
6000
© European Medicines Agency,
2023. Reproduction is authorised provided the source is acknowledged.
Informazioni aggiornate su questo medicinale veterinario sono
disponibili sul sito web Veterinary
Medicines.
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 31-01-2024
Public Assessment Report Public Assessment Report Bulgarian 29-01-2024
Patient Information leaflet Patient Information leaflet Spanish 31-01-2024
Public Assessment Report Public Assessment Report Spanish 29-01-2024
Patient Information leaflet Patient Information leaflet Czech 31-01-2024
Public Assessment Report Public Assessment Report Czech 29-01-2024
Patient Information leaflet Patient Information leaflet Danish 31-01-2024
Public Assessment Report Public Assessment Report Danish 29-01-2024
Patient Information leaflet Patient Information leaflet German 31-01-2024
Public Assessment Report Public Assessment Report German 29-01-2024
Patient Information leaflet Patient Information leaflet Estonian 31-01-2024
Public Assessment Report Public Assessment Report Estonian 29-01-2024
Patient Information leaflet Patient Information leaflet Greek 31-01-2024
Public Assessment Report Public Assessment Report Greek 29-01-2024
Patient Information leaflet Patient Information leaflet English 31-01-2024
Public Assessment Report Public Assessment Report English 29-01-2024
Patient Information leaflet Patient Information leaflet French 31-01-2024
Public Assessment Report Public Assessment Report French 29-01-2024
Patient Information leaflet Patient Information leaflet Latvian 31-01-2024
Public Assessment Report Public Assessment Report Latvian 29-01-2024
Patient Information leaflet Patient Information leaflet Lithuanian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 31-01-2024
Public Assessment Report Public Assessment Report Lithuanian 29-01-2024
Patient Information leaflet Patient Information leaflet Hungarian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 31-01-2024
Public Assessment Report Public Assessment Report Hungarian 29-01-2024
Patient Information leaflet Patient Information leaflet Maltese 31-01-2024
Public Assessment Report Public Assessment Report Maltese 29-01-2024
Patient Information leaflet Patient Information leaflet Dutch 31-01-2024
Public Assessment Report Public Assessment Report Dutch 29-01-2024
Patient Information leaflet Patient Information leaflet Polish 31-01-2024
Public Assessment Report Public Assessment Report Polish 29-01-2024
Patient Information leaflet Patient Information leaflet Portuguese 31-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 31-01-2024
Public Assessment Report Public Assessment Report Portuguese 29-01-2024
Patient Information leaflet Patient Information leaflet Romanian 31-01-2024
Public Assessment Report Public Assessment Report Romanian 29-01-2024
Patient Information leaflet Patient Information leaflet Slovak 31-01-2024
Public Assessment Report Public Assessment Report Slovak 29-01-2024
Patient Information leaflet Patient Information leaflet Slovenian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 31-01-2024
Public Assessment Report Public Assessment Report Slovenian 29-01-2024
Patient Information leaflet Patient Information leaflet Finnish 31-01-2024
Public Assessment Report Public Assessment Report Finnish 29-01-2024
Patient Information leaflet Patient Information leaflet Swedish 31-01-2024
Public Assessment Report Public Assessment Report Swedish 29-01-2024
Patient Information leaflet Patient Information leaflet Norwegian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 31-01-2024
Public Assessment Report Public Assessment Report Norwegian 29-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 31-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 31-01-2024
Public Assessment Report Public Assessment Report Icelandic 29-01-2024
Patient Information leaflet Patient Information leaflet Croatian 31-01-2024
Public Assessment Report Public Assessment Report Croatian 29-01-2024

Search alerts related to this product

View documents history